Aura Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:AURA Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
07 May 26	SellUS$39,044,987	Matrix Capital Management Company, LP	Company	6,922,870	US$5.64
16 Apr 26	SellUS$82,401	Conor Kilroy	Individual	11,738	US$7.02
17 Feb 26	SellUS$43,258	Amy Elazzouzi	Individual	8,549	US$5.06
17 Feb 26	SellUS$80,245	Mark Plavsic	Individual	15,890	US$5.05
17 Feb 26	SellUS$241,099	Elisabet de los Pinos	Individual	47,648	US$5.06
17 Feb 26	SellUS$103,229	Jill Hopkins	Individual	20,401	US$5.06
17 Feb 26	SellUS$60,999	Conor Kilroy	Individual	12,079	US$5.05
20 Jan 26	SellUS$7,684	Amy Elazzouzi	Individual	1,581	US$4.86
20 Jan 26	SellUS$82,270	Elisabet de los Pinos	Individual	16,928	US$4.86
17 Nov 25	SellUS$92,731	Jill Hopkins	Individual	17,109	US$5.42
29 Oct 25	SellUS$5,690	Amy Elazzouzi	Individual	896	US$6.35
29 Oct 25	SellUS$57,461	Elisabet de los Pinos	Individual	9,049	US$6.35

Insider Trading Volume

Insider Buying: AURA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of AURA?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	1,143,608	1.04%
VC/PE Firms	9,533,333	8.64%
Institutions	48,042,300	43.6%
General Public	51,580,187	46.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 77.9%.

Top Shareholders

Top 25 shareholders own 49.08% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.64%	TCG Crossover Management, LLC	9,533,333	US$58.3m	0%	1.66%
4.62%	Frazier Life Sciences Management, LP	5,100,000	US$31.2m	0%	0.86%
4.43%	Adage Capital Management, L.P.	4,881,125	US$29.9m	0%	0.04%
4.19%	Long Focus Capital Management LLC	4,619,582	US$28.3m	0%	1.18%
3.96%	Suvretta Capital Management, LLC	4,372,884	US$26.8m	0%	0.67%
3.25%	BlackRock, Inc.	3,586,640	US$22.0m	0.74%	no data
2.76%	Medicxi Ventures (UK) LLP	3,039,892	US$18.6m	0%	2.0%
2.03%	Vanguard Capital Management, LLC	2,243,828	US$13.7m	0%	no data
1.92%	Nantahala Capital Management, LLC	2,117,697	US$13.0m	0%	0.84%
1.88%	Franklin Resources, Inc.	2,072,186	US$12.7m	-5.73%	no data
1.83%	Advent Life Sciences LLP	2,023,857	US$12.4m	0%	100.0%
1.59%	Lundbeckfonden BioCapital	1,750,108	US$10.7m	0%	0.14%
1.19%	Geode Capital Management, LLC	1,310,862	US$8.0m	4.41%	no data
1%	Millennium Management LLC	1,097,627	US$6.7m	77.8%	no data
0.87%	State Street Global Advisors, Inc.	964,670	US$5.9m	4.12%	no data
0.85%	Levin Capital Strategies, L.P.	941,400	US$5.8m	-9.09%	0.42%
0.54%	The B Group, Inc.	597,576	US$3.7m	4.37%	2.76%
0.54%	Acorn Bioventures	595,744	US$3.6m	0%	1.3%
0.51%	Dimensional Fund Advisors LP	558,158	US$3.4m	7.77%	no data
0.51%	Balyasny Asset Management L.P.	557,654	US$3.4m	0%	0.01%
0.48%	Regency Capital Management Inc.	532,495	US$3.3m	-1.13%	1.44%
0.39%	Northern Trust Global Investments	430,522	US$2.6m	4.29%	no data
0.38%	T. Rowe Price Group, Inc.	415,191	US$2.5m	-6.23%	no data
0.36%	Vanguard Fiduciary Trust Company	397,160	US$2.4m	10.5%	no data
0.35%	Vanguard Portfolio Management, LLC	391,334	US$2.4m	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 04:48
End of Day Share Price	2026/06/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aura Biosciences, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Wolleben	Citizens JMP Securities, LLC
Liisa Bayko	Evercore ISI
Edward White	H.C. Wainwright & Co.